Erratum: A phase II, multicenter, open-label, 3-cohort trial evaluating the efficacy and safety of vismodegib in operable basal cell carcinoma (Journal of the American Academy of Dermatology (2015) 73 (99-105))

H. Sofen, K. G. Gross, Leonard Harry Goldberg

Research output: Contribution to journalArticle

Fingerprint Dive into the research topics of 'Erratum: A phase II, multicenter, open-label, 3-cohort trial evaluating the efficacy and safety of vismodegib in operable basal cell carcinoma (Journal of the American Academy of Dermatology (2015) 73 (99-105))'. Together they form a unique fingerprint.